Inhibikase Therapeutics (IKT) Competitors $2.24 -0.02 (-0.88%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.24 0.00 (0.00%) As of 05/1/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IKT vs. ANAB, KALV, ABUS, TRVI, CDXC, PHAR, ORGO, CRMD, BCYC, and IMTXShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), Trevi Therapeutics (TRVI), ChromaDex (CDXC), Pharming Group (PHAR), Organogenesis (ORGO), CorMedix (CRMD), Bicycle Therapeutics (BCYC), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. AnaptysBio KalVista Pharmaceuticals Arbutus Biopharma Trevi Therapeutics ChromaDex Pharming Group Organogenesis CorMedix Bicycle Therapeutics Immatics Inhibikase Therapeutics (NYSE:IKT) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking. Does the MarketBeat Community prefer IKT or ANAB? AnaptysBio received 367 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Inhibikase Therapeutics an outperform vote while only 66.31% of users gave AnaptysBio an outperform vote. CompanyUnderperformOutperformInhibikase TherapeuticsOutperform Votes975.00% Underperform Votes325.00% AnaptysBioOutperform Votes37666.31% Underperform Votes19133.69% Is IKT or ANAB more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. AnaptysBio's return on equity of -287.94% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% AnaptysBio -289.75%-287.94%-37.25% Which has more volatility and risk, IKT or ANAB? Inhibikase Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Do analysts prefer IKT or ANAB? Inhibikase Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 190.18%. AnaptysBio has a consensus price target of $33.63, suggesting a potential upside of 54.95%. Given Inhibikase Therapeutics' higher probable upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70 Does the media favor IKT or ANAB? In the previous week, AnaptysBio had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for AnaptysBio and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.65 beat AnaptysBio's score of 1.18 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AnaptysBio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of IKT or ANAB? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 4.6% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 33.7% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, IKT or ANAB? Inhibikase Therapeutics has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K640.48-$19.03M-$2.67-0.84AnaptysBio$91.28M7.29-$163.62M-$5.21-4.17 SummaryInhibikase Therapeutics beats AnaptysBio on 10 of the 19 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$166.53M$2.95B$5.54B$18.96BDividend YieldN/A1.89%5.09%4.01%P/E Ratio-0.8430.0722.5532.87Price / Sales640.48494.82395.2528.03Price / CashN/A168.6838.1817.52Price / Book1.263.176.764.47Net Income-$19.03M-$72.35M$3.22B$1.02B7 Day Performance6.16%2.14%1.37%0.59%1 Month Performance2.75%5.67%2.77%-3.54%1 Year Performance67.16%-23.57%15.59%3.80% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.5469 of 5 stars$2.24-0.9%$6.50+190.2%+65.9%$166.53M$260,000.00-0.846Positive NewsANABAnaptysBio2.5149 of 5 stars$21.33+3.0%$33.63+57.6%-16.6%$654.13M$91.28M-3.51100Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsKALVKalVista Pharmaceuticals3.9024 of 5 stars$13.00+0.1%$24.83+91.0%+11.7%$646.31MN/A-3.57100Positive NewsABUSArbutus Biopharma2.0048 of 5 stars$3.34+1.5%$5.50+64.7%+34.2%$639.54M$6.17M-7.7790Positive NewsTRVITrevi Therapeutics3.5994 of 5 stars$6.59+1.9%$17.56+166.5%+141.3%$637.13MN/A-14.9820Upcoming EarningsNews CoveragePositive NewsCDXCChromaDex2.328 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastPHARPharming Group2.5089 of 5 stars$8.75+2.8%$30.00+242.9%-15.0%$595.27M$297.20M-33.65280Upcoming EarningsShort Interest ↓Positive NewsGap UpORGOOrganogenesis3.4229 of 5 stars$4.67+2.4%$5.50+17.8%+97.6%$592.29M$482.04M-77.83950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.4918 of 5 stars$9.06-0.4%$14.50+60.0%+74.8%$590.55M$43.47M-11.1930Upcoming EarningsPositive NewsBCYCBicycle Therapeutics3.0462 of 5 stars$8.40-0.2%$29.14+246.9%-62.5%$581.30M$35.28M-2.55240Analyst ForecastShort Interest ↓News CoverageIMTXImmatics2.0566 of 5 stars$4.77+5.5%$16.67+249.4%-53.7%$579.79M$155.84M-7.23260Positive News Related Companies and Tools Related Companies ANAB Alternatives KALV Alternatives ABUS Alternatives TRVI Alternatives CDXC Alternatives PHAR Alternatives ORGO Alternatives CRMD Alternatives BCYC Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IKT Stock Free IKT Stock Alerts